Business Wire

Developing Telecoms Believes China Already Has the Ability to Mass Produce 28nm Chips

11.11.2020 14:00:00 EET | Business Wire | Press release

Share

Developing Telecoms learnt from Li Ke from China Semiconductor Industry Association (CSIA) that the race of chips and the manufacturing of equipment is on to develop home grown solutions, and China already has a presence in the key areas which needed to move toward mid-to-high-end chip production. Li Ke believes that Chinese 28nm chips which can meet most of the market demand will be mass produced in one or two years.

Last year, China's IC industry generated over CNY750 billion and this is expected to reach CNY900 billion in 2020. Shared by Li Ke, IC manufacturing has made the greatest progress among the entire IC industry. China's IC production capacity last year was more than 20% of the world total, larger than any other single country. Li Ke thinks that the narrowing gap between China's IC manufacturing and the world-leading technologies is laying a solid foundation for the prominence of its IC industry, and a domestic chip manufacturing industry chain will be emerged with further advanced technologies.

Li Ke also stresses on the importance of producing 28nm chips. As mentioned by Li Ke, 28nm is the dividing line between low to mid-range and mid-to-high end IC manufacturing. Being able to produce 28nm chips means it can meet most of the demand for chips without relying on others.

Chinese government is actively backing for the chip sector. The State Council has issued the document "Several Policies for Facilitating the High-quality Development of the Integrated Circuit Industry and Software Industry in the New Era", which in part outlines new tax incentives for fabs and companies that use 28nm or smaller technologies. Other policies like "qualified integrated circuit projects or enterprises that have operated for more than 15 years shall be exempt from corporate income tax for the first ten years if they employ the 28nm process or more advanced nodes" is also included.

Developing Telecoms believes China already has the ability to mass produce 28nm chips completely on its own. After more than a decade, China has a presence at every part of the 28nm-technology industry chain and every major aspect for the strategic materials. National-level and joint enterprises projects are also advancing in key parts of China's 28nm chip industry chain such as lithography machines.

About Developing Telecoms

Developing Telecoms is the leading online news portal for telecoms in emerging markets, delivering telecommunications news and information for senior management and decision makers at network operators, governments and end users. Developing Telecoms receives 2.2 million yearly page views and gets over 760,000 yearly online visitors. Its weekly emerging markets newsletter has over 40,000 subscribers. Developing Telecoms publishes a range of special reports about telecoms in emerging markets spanning topics including 5G, IoT, Smart Cities and Last Mile Connectivity.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Alec Barton
+44 7799 417751
alec@developingtelecoms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye